Reckitt Benckiser Group plc (RKT) has announced that Andrew Bonfield, its Senior Independent Director and Non-Executive Director, will take on an additional Non-Executive Director role at BP plc (LSE: BP), effective 1 December 2026. The disclosure was made in accordance with UK Listing Rule 6.4.9R(2), which requires listed companies to notify the market of certain director appointments at other organisations. The development draws attention to Bonfield's expanding board commitments across two major FTSE-listed companies. Investors in Reckitt may wish to monitor whether his additional responsibilities prompt any further governance commentary from the company.

Key Points

  • Reckitt Benckiser Group plc (RKT) made the notification via RNS on 17 November 2026
  • Andrew Bonfield, Senior Independent Director and Non-Executive Director, has been appointed Non-Executive Director of BP plc with effect from 1 December 2026
  • The disclosure was made under UK Listing Rule 6.4.9R(2); no financial terms or remuneration details were provided
  • Investors should watch for any further board or governance updates from Reckitt relating to Bonfield's dual non-executive commitments

Andrew Bonfield to Join BP plc Board While Retaining Reckitt Senior Independent Director Role

Reckitt Benckiser confirmed in its 17 November 2026 announcement that Andrew Bonfield will assume a Non-Executive Director position at BP plc from 1 December 2026, while continuing to serve as Senior Independent Director and Non-Executive Director at Reckitt. The company made the notification strictly in line with its obligations under UK Listing Rule 6.4.9R(2), which mandates disclosure when a director of a premium or commercial company listed in the United Kingdom accepts a directorship at another listed entity. No further details regarding Bonfield's specific responsibilities at BP were included in the announcement.

Reckitt's Global Consumer Health and Hygiene Portfolio Provides the Governance Context

Reckitt is a global consumer health and hygiene business founded in the United Kingdom in 1840, operating across more than 80 countries and selling approximately 30 million products daily. The company employs around 36,000 people worldwide and markets well-known brands including Dettol, Durex, Nurofen, Gaviscon, Strepsils, Finish, Harpic, Lysol, Mucinex, Vanish, and Veet across four categories: Germ Protection, Household Care, Intimate Wellness, and Self Care. Its broad geographic and brand footprint means board-level governance is a material consideration for institutional shareholders closely watching the composition of Reckitt's independent leadership.

UK Listing Rule 6.4.9R(2) Drives the Mandatory Disclosure Requirement

The regulatory basis for this notification is UK Listing Rule 6.4.9R(2), which obliges listed companies to inform the market when a director takes on a new directorship at another listed organisation. This framework is designed to support transparency and allow investors to assess potential conflicts of interest or time commitments at board level. Reckitt's announcement contained no indication that Bonfield's new role at BP raises any conflict concerns, and the company provided no additional commentary beyond confirming the appointment and its effective date.